Oxaliplatin-safety profile: neurotoxicity
- PMID: 14523789
- DOI: 10.1016/s0093-7754(03)00399-3
Oxaliplatin-safety profile: neurotoxicity
Abstract
Oxaliplatin has become an integral part of various chemotherapy protocols, and in advanced colorectal cancer in particular. While oxaliplatin has only mild hematologic and gastrointestinal side effects, its dose-limiting toxicity is a cumulative sensory neurotoxicity that resembles that of cisplatin with the important difference of a more rapid and complete reversibility. The reversibility of neurotoxicity has been assured in long-term follow-up of patients who have received adjuvant oxaliplatin-based chemotherapy. In addition, oxaliplatin causes a very unique, but frequent, acute sensory neuropathy that is triggered or aggravated by exposure to cold but is rapidly reversible, without persistent impairment of sensory function. Various strategies have been proposed to prevent or treat oxaliplatin-induced neurotoxicity. The "Stop-and-Go" concept uses the reversibility of neurologic symptoms to aim at delivering higher cumulative oxaliplatin doses as long as the therapy is still effective. Several neuromodulatory agents such as calcium-magnesium infusions, antiepileptic drugs like carbamazepine or gabapentin, amifostine, alpha-lipoic acid, and glutathione have shown promising activity in prophylaxis and treatment of oxaliplatin-induced neurotoxicity. However, larger confirmatory trials are still lacking so that, to date, no evidence-based recommendation can be given for the prophylaxis of oxaliplatin-induced neurotoxicity. The predictability of neurotoxicity associated with oxaliplatin-based therapy should allow patients and doctors to develop strategies to manage this side effect in view of the individual patient's clinical situation.
Similar articles
-
Clinical management of oxaliplatin-associated neurotoxicity.Clin Colorectal Cancer. 2005 Apr;5 Suppl 1:S38-46. doi: 10.3816/ccc.2005.s.006. Clin Colorectal Cancer. 2005. PMID: 15871765 Review.
-
Oral Calcium Ameliorating Oxaliplatin-Induced Peripheral Neuropathy.J Appl Res. 2004 Jan 1;4(4):576-582. J Appl Res. 2004. PMID: 19816592 Free PMC article.
-
Prevention of oxaliplatin-induced peripheral sensory neuropathy by carbamazepine in patients with advanced colorectal cancer.Clin Colorectal Cancer. 2002 May;2(1):54-8. doi: 10.3816/CCC.2002.n.011. Clin Colorectal Cancer. 2002. PMID: 12453338
-
[Prevention of oxaliplatin-induced neuropathy by carbamazepine. A pilot study].Dtsch Med Wochenschr. 2002 Jan 18;127(3):78-82. doi: 10.1055/s-2002-19594. Dtsch Med Wochenschr. 2002. PMID: 11797144 German.
-
Oxaliplatin-associated neuropathy: a review.Ann Pharmacother. 2005 Jan;39(1):128-35. doi: 10.1345/aph.1E319. Epub 2004 Dec 8. Ann Pharmacother. 2005. PMID: 15590869 Review.
Cited by
-
Ganglioside-monosialic acid (GM1) prevents oxaliplatin-induced peripheral neurotoxicity in patients with gastrointestinal tumors.World J Surg Oncol. 2013 Jan 25;11:19. doi: 10.1186/1477-7819-11-19. World J Surg Oncol. 2013. PMID: 23351188 Free PMC article. Clinical Trial.
-
Neurological adverse effects caused by cytotoxic and targeted therapies.Nat Rev Clin Oncol. 2009 Oct;6(10):596-603. doi: 10.1038/nrclinonc.2009.128. Epub 2009 Aug 25. Nat Rev Clin Oncol. 2009. PMID: 19707193 Review.
-
Transient Receptor Potential Vanilloid 1 is essential for cisplatin-induced heat hyperalgesia in mice.Mol Pain. 2010 Mar 5;6:15. doi: 10.1186/1744-8069-6-15. Mol Pain. 2010. PMID: 20205720 Free PMC article.
-
Detecting acute neurotoxicity during platinum chemotherapy by neurophysiological assessment of motor nerve hyperexcitability.BMC Cancer. 2010 Aug 23;10:451. doi: 10.1186/1471-2407-10-451. BMC Cancer. 2010. PMID: 20731872 Free PMC article.
-
Recommendations for follow-up of colorectal cancer survivors.Clin Transl Oncol. 2019 Oct;21(10):1302-1311. doi: 10.1007/s12094-019-02059-1. Epub 2019 Feb 14. Clin Transl Oncol. 2019. PMID: 30762206
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical